HP missed estimates on its first quarter revenue as the PC market continues to struggle.
Tech ETFs saw massive inflows of over $17 billion last year, according to VettaFi. However, Financial Futurist Dave Nadig, says many are "overdone" in mega-caps like Nvidia (NVDA) and Meta (META) which drive gains. He warns of "concentration risks," noting that in the Technology Select Spdr Fund (XLK) just 5 names account for more than 50% of the fund. Nadig advises those investing in tech to "look for strategies that are a little bit more equal-weighted." He suggests something like the Robo Global Robotics and Automation Index ETF (ROBO) which is "much more balanced" with global diversification across use cases. Many tech ETFs have "hyper-concentrated" portfolios, with stocks like Microsoft (MSFT), for example, dominating the top holdings. On the days that dominate stock does well, "performance will beat everybody else," while down days see similar exaggerated moves. Nadig recommends focusing on long-term plays that "benefit over the cycle, not just over the headline." Beyond tech, Nadig highlights healthcare as an attractive sector, suggesting the Simplify Healthcare ETF (PINK) for exposure without "veering entirely" into biotech/pharma - providing "nice balance." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith
The so-called Magnificent Seven mega-cap stocks have powered much of the S&P 500's gains. However, their dominant run may be ending, according to JonesTrading Chief Market Strategist Mike O'Rourke. O'Rourke pointed to recent earnings from Meta (META) and Nvidia (NVDA) that "shattered" expectations yet saw different market reactions. He notes the Magnificent Seven valuations have diverged "drastically," causing investors to "differentiate" between them rather than treat them as a uniform group. As growth moderates for these mega-cap stocks, O'Rourke expects "rotation" within the Magnificent Seven tech companies as investors compare valuations and future trajectories. He believes this could force funds into other promising areas of the market beyond the narrow mega-cap technology focus, like biotech and pharma. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith